Oligonucleotide News and Research

RSS

Aptamer Group and Alphazyme execute licensing agreement for synthetic aptamer-based enzyme modulation in hot-start PCR

Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company specializing in enzymes for molecular biology, have executed a licensing agreement for a proprietary Optimer® binder developed for hot-start polymerase chain reaction (PCR) applications.

From Aptamer Group 24 Dec 2025

Tau biology expands beyond microtubules to neurodegeneration, metabolism and mental illness

An Thought Leaders Invited Review published today in Genomic Psychiatry by Dr. Peng Lei and colleagues presents a sweeping synthesis of tau protein research that fundamentally reframes our understanding of this molecule's dual identity.

16 Dec 2025

Top-five pharmaceutical company expands partnership with Aptamer for multi-target Optimer® development program

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new contract valued at up to £617,000 with a top-five pharmaceutical company.

4 Nov 2025

Study reveals how TDP-43 causes neuronal overactivity in ALS and FTD

A new Northwestern University study using patient nervous tissue and lab-grown human neurons has uncovered how a key disease protein, TDP-43, drives overactive nerve cells in the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

31 Oct 2025

How shifting antibodies fuel aging and the new therapies aiming to slow it

This review uncovers how aging reshapes immunoglobulins, particularly IgG, IgM, and IgA, driving inflammation, cellular senescence, and tissue degeneration. By dissecting B-cell dysfunction, glycosylation changes, and Fc receptor pathways, it reveals immunoglobulins as both biomarkers and potential therapeutic targets in aging.

14 Oct 2025

Picoquant invests in Fluobrick Solutions to simplify access to single molecule research

PicoQuant GmbH announces its investment in FluoBrick Solutions GmbH, a newly founded Berlin-based start-up focused on giving life science researchers in academia and pharma diagnostics access to the power of single molecule techniques.

25 Sep 2025

Scientists unveil new obesity drug that reprograms fat and energy use

Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September).

18 Sep 2025

Aptamer signs therapeutic development agreement with Invizius

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce that it has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology company focused on second-generation complement system therapies for inflammatory, fibrotic, and autoimmune diseases.

From Aptamer Group 2 Sep 2025

First clinical trial in cats tests targeted therapy for deadly head and neck cancer

Researchers have reported results from the first-ever clinical trial of a new class of targeted therapy in pet cats with head and neck squamous cell carcinoma (HNSCC)-a cancer which is notoriously deadly and difficult to treat.

28 Aug 2025

Aptamer Group introduces novel biomarker discovery service

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announced the launch of its biomarker discovery service, offering researchers in pharmaceutical, biotechnology, and diagnostic development an innovative approach to identify and validate new disease markers.

28 Aug 2025

Scientists discover molecular brake that halts brain cell repair in multiple sclerosis

A team of scientists led by the Institute for Glial Sciences (IGS) at Case Western Reserve University's School of Medicine has discovered a built-in "brake" that controls when key brain cells mature.

25 Aug 2025

Breakthroughs in diagnosis and therapy for transthyretin amyloidosis

Transthyretin amyloidosis (ATTR) is caused by the misfolding and aggregation of the transthyretin (TTR) protein, leading to multi-organ damage.

21 Aug 2025

Triglycerides identified as direct cause of abdominal aortic aneurysms

High levels of triglycerides, the most common type of fat in the body and the foods we eat, directly cause abdominal aortic aneurysms, according to a study in mouse models led by Michigan Medicine.

14 Aug 2025

Characterization of antibodies targeting ASO modifications for intracellular trafficking

A new article in the peer-reviewed journal Nucleic Acid Therapeutics describes the characterization of antibodies targeting antisense oligonucleotide (ASO) phosphorothioate and 2'-methoxyehtyl modifications for intracellular trafficking and biodistribution studies.

1 Aug 2025

Experimental ALS drug shows unprecedented recovery in some patients

When Columbia neurologist and scientist Neil Shneider speaks to his ALS patients who volunteer for experimental therapies, he's unwaveringly honest.

23 May 2025

Aptamer announces new data at ASGCT

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, presented new data on its Optimer therapeutic delivery vehicle for liver fibrosis at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in New Orleans, LA (13-17 May 2025).

From Aptamer Group 16 May 2025

ELRIG announces Prof Rory Johnson and Dr Shalini Andersson as keynote speakers at Therapeutic Oligonucleotides 2025

ELRIG, a not-for-profit, volunteer-led organization for the drug discovery community, today announced the keynote speakers for Therapeutic Oligonucleotides 2025 taking place at the AstraZeneca R&D site in Gothenburg, Sweden from 14-15 May. Prof Rory Johnson, Associate Professor, University College Dublin, and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, AstraZeneca will lead this year's event focused on 'drugging the undruggable'.

25 Mar 2025

New approach to combat cancer by reactivating natural RNA kill switch

Alternative RNA splicing is like a movie editor cutting and rearranging scenes from the same footage to create different versions of a film.

14 Mar 2025

First insights into familial ALS in Egypt reveal genetic variations and disease progression

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration of motor neurons, leading to muscle weakness and eventually death.

18 Feb 2025

Researchers develop new approach to effectively deliver therapeutics into the brain

Researchers at the Icahn School of Medicine at Mount Sinai have developed an innovative approach - demonstrated in mouse models and isolated human brain tissue - to safely and effectively deliver therapeutics into the brain, providing new possibilities for treating a wide range of neurological and psychiatric diseases.

25 Nov 2024